Biogen
BIIB
1,031 hedge funds and large institutions have $34.2B invested in Biogen in 2022 Q4 according to their latest regulatory filings, with 159 funds opening new positions, 325 increasing their positions, 362 reducing their positions, and 96 closing their positions.
66% more first-time investments, than exits
New positions opened: 159 | Existing positions closed: 96
14% more funds holding in top 10
Funds holding in top 10: 22 → 25 (+3)
5% more funds holding
Funds holding: 986 → 1,031 (+45)
1.43% more ownership
Funds ownership: 85.29% → 86.72% (+1.4%)
4% more capital invested
Capital invested by funds: $32.8B → $34.2B (+$1.4B)
10% less repeat investments, than reductions
Existing positions increased: 325 | Existing positions reduced: 362
14% less call options, than puts
Call options by funds: $1.29B | Put options by funds: $1.51B
Top Buyers
| 1 |
Marshall Wace
London,
United Kingdom
|
+$309M |
| 2 |
BlackRock
New York
|
+$117M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$84.7M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$81.1M |
| 5 |
Barclays
London,
United Kingdom
|
+$81M |
Top Sellers
| 1 |
Millennium Management
New York
|
-$162M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$160M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$128M |
| 4 |
Goldman Sachs
New York
|
-$118M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$114M |
BIIB Hedge Fund Activity: Q4 2022 in Review
1,031 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q4 2022, worth a combined $34.2B — up 4.3% from $32.8B a quarter earlier.
Buyers outnumbered sellers: 159 funds opened new BIIB positions and 96 closed out — a net gain of 63 holders — while 325 added to existing stakes and 362 trimmed.
The largest buyer was Marshall Wace, adding an estimated $309M. The largest seller was Millennium Management, cutting an estimated $162M.
- 1,031 institutional investors held Biogen (BIIB) as of Q4 2022, up from 986 in Q3 2022.
- Funds reported $34.2B of Biogen stock for Q4 2022, up 4.3% quarter-over-quarter.
- 159 funds opened new Biogen positions in Q4 2022 and 96 closed out, a net change of +63 holders.
- The largest Biogen buyer in Q4 2022 was Marshall Wace, an estimated $309M added.
- The largest Biogen seller in Q4 2022 was Millennium Management, an estimated $162M sold.
Based on aggregated 13F filings for Q4 2022.